The Substance Use Disorder Committee is responsible for developing tools and educational resources for pharmacists. Additionally, the Committee assists the government affairs committee when information is needed to support comment letters or issue briefs related to regulatory or legislative actions or possible actions. (Meets: Virtually 1-hour monthly and in-person at Annual Meeting, Time Commitment: Average of 2-3 hours per month or 25-30 hours approximately over course of the year)
1. Education
|
a. Update and manage the Opioid Use Disorders curriculum should it be determined that it has value in the context of the X-Waiver elimination with education requirements still pending. |
b. Recommend partner organizations to involve in the planning and/or co-sponsorship of educational activities. |
c. Continue organizational involvement in PCSS as a conduit to education and mentoring in the area of SUD. |
d. Contribute recommendations to the AAPP Program and Recertification Committees for educational programs to include in the 2024 Annual Meeting and 2024 Summit respectively.
|
2. Resources
|
a. Assess the need for additional toolkits and other resources and, if need is determined, develop and implement accordingly. |
b. Make outreach to the VA to discuss and learn from their early adoption efforts. Consider developing a proposal to the Board of Directors to work together to promote results and develop tools and materials allowing for modeling in the private sector. |
c. Evaluate the success and value of the SUD Case Based Peer-to-Peer webinars implemented in spring of 2023 and make recommendations related to future offerings including consideration of escalating to SUD practice hubs and/or a Transformative Learning Collaborative (TLC) offering in an area of SUD as means to provide tools, resources, logistics/systems, and billing guidance to help members build practices addressing SUD and/or co-occurring mental health and substance use disorders.
|
i. Depending on above considerations, work with staff to develop a proposal to the AAPP Board related to content, value, costs, practicality, appropriate timing and other considerations.
|
3. Advocacy
|
a. Recommend papers on the role of psychiatric pharmacists in the treatment of SUD for consideration by the new AAPP Commission on Innovation and Advancement. |
b. Support the Government Affairs and Professional Affair Committee efforts (comment letters, conference proposals, other deliverables, projects) where requested. |
c. Explore and develop a preliminary concept around working in cooperation with addiction medicine partners to seek funding for a Summit of stakeholders to identify and define the roles pharmacists can play in the area of substance use disorders treatment and develop a resulting roadmap to get there. |
d. Explore how AAPP can support pharmacy residencies in enhancing the experience in substance use disorders.
|